Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
709 stopped studies mapped to Hepatopancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 709 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | Phase 1 | terminated | Aug 6, 2020 | Eureka Therapeutics Inc. | The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to… | Other (stated, no rule matched) |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | Phase 2 | terminated | Aug 18, 2021 | National Cancer Institute (NCI) | Reason for termination was a combination of slow accrual in setting of austerity measures regarding… | Enrollment / accrual |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular…(HOMIE-166) | N/A | terminated | Jul 11, 2022 | Terumo Europe N.V. | The HOMIE-166 clinical investigation was prematurely terminated due to sponsor's decision to… | Sponsor / business decision |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
| NCT02784795 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | terminated | May 27, 2016 | Eli Lilly and Company | The study was terminated due to business considerations | Sponsor / business decision |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib… | Phase 1 | terminated | Aug 4, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | Phase 2 | terminated | Oct 28, 2019 | University of Nebraska | Due to low accrual and futility | Efficacy / futility |
| NCT02070705 | DCE MRI in Patients With Pancreatic Cancer | N/A | terminated | Feb 25, 2014 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Phase 2 | terminated | Oct 20, 2017 | University Health Network, Toronto | The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further… | Enrollment / accrual |
| NCT07043348 | Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma(ISTAR-04) | — | terminated | Jun 29, 2025 | Seoul National University Hospital | This study was merged with NCT07043387. Thus, this study was terminated. | Other (stated, no rule matched) |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04561453 | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer | — | terminated | Sep 23, 2020 | University of Washington | Study terminated due to end of funding | Funding |
| NCT04992507 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | Phase 2 | terminated | Aug 5, 2021 | Ohio State University Comprehensive Cancer Center | Principal investigator departed sponsoring organization | Investigator |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04520906 | To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With… | N/A | terminated | Aug 20, 2020 | Suzhou Hengruihongyuan Medical Technology Co. LTD | Obtaining medical device market approval through the predicate device comparison route. | Other (stated, no rule matched) |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic… | Early Phase 1 | withdrawn | Aug 27, 2024 | Shanghai Changzheng Hospital | Based on the results of another intravenous injection therapy CD-801 for the treatment of… | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma… | Phase 2 | terminated | Apr 17, 2024 | Shandong Cancer Hospital and Institute | Study was terminated due to unacceptable treatment-related toxicity that raised safety concerns and… | Safety / toxicity |
| NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | Phase 1 | withdrawn | Nov 27, 2024 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable… | Phase 1 / Phase 2 | terminated | Nov 30, 2022 | Nerviano Medical Sciences | In the Phase II part of the study, among the participants evaluable for efficacy, no objective… | Efficacy / futility |
| NCT05342350 | International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy(STOP-HCC) | — | terminated | Apr 22, 2022 | Johns Hopkins University | PI moving on from current institution | Other (stated, no rule matched) |
| NCT05841706 | Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients… | Early Phase 1 | terminated | May 3, 2023 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC(FORTIFIDE) | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Lisata Therapeutics, Inc. | Management Decision | Other (stated, no rule matched) |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | suspended | Nov 2, 2022 | Primocure Pharma | Enrollment paused | Enrollment / accrual |
| NCT05287347 | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | — | withdrawn | Mar 18, 2022 | Beth Israel Deaconess Medical Center | Lack of funding | Funding |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | Phase 2 | withdrawn | Apr 12, 2024 | Shanghai Zhongshan Hospital | The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted… | Other (stated, no rule matched) |
| NCT06077487 | Ketamine-assisted Therapy for Advanced GI Cancer | Phase 4 | terminated | Oct 11, 2023 | Brian Anderson, MD | Slow Accrual | Enrollment / accrual |
| NCT03534141 | Mild Hypothermia and Acute Kidney Injury in Liver Transplantation(MHALT) | N/A | terminated | May 23, 2018 | University of California, San Francisco | Terminated 9/24/23 at 85% target enrollment due to slow accrual of subjects. The decline in… | Enrollment / accrual |
| NCT04965311 | Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic… | Phase 2 | terminated | Jul 16, 2021 | OHSU Knight Cancer Institute | low enrollment | Enrollment / accrual |
| NCT02807181 | SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line…(SIRCCA) | Phase 2 / Phase 3 | terminated | Jun 21, 2016 | Sirtex Medical | Slow enrollment | Enrollment / accrual |
| NCT04732286 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With… | Phase 3 | terminated | Feb 1, 2021 | Hoffmann-La Roche | The study was completed as pre-specified in the protocol. Study was terminated only for… | Other (stated, no rule matched) |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or… | Phase 1 | terminated | Feb 16, 2022 | Kinnate Biopharma | Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor… | Enrollment / accrual |
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Dec 18, 2019 | Helix BioPharma Corporation | The primary reason for early termination was budget constraint. | Funding |
| NCT05251233 | Role of Proton Pump Inhibitors on the Postoperative Course Following… | Phase 2 | terminated | Feb 22, 2022 | Washington University School of Medicine | Investigator and study team chose to end study early. | Investigator |
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With… | — | withdrawn | Apr 10, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | No subjects were enrolled. Study team was not able to grow cell lines for the tumors. | Enrollment / accrual |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients… | Phase 1 | terminated | Mar 7, 2023 | Coherus Oncology, Inc. | The study was terminated for strategic reasons (not for safety concerns) | Safety / toxicity |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced… | Phase 2 | withdrawn | Dec 15, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | PI Left institution on 8/6/2018 and study has been final reported with IRB. Never opened to accrual | Investigator |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular… | Phase 2 | withdrawn | Oct 20, 2016 | Medical University of South Carolina | study is being rewritten for different disease population | Other (stated, no rule matched) |
| NCT05448677 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First…(ABE-LIVER) | Phase 2 | terminated | Jul 7, 2022 | University Hospital, Grenoble | Study terminated due to recruitement issues | Enrollment / accrual |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05565794 | Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements | Phase 2 | terminated | Oct 4, 2022 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | slow recruitment | Enrollment / accrual |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | terminated | Feb 21, 2023 | Mirati Therapeutics Inc. | Formulation challenges | Other (stated, no rule matched) |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05494866 | A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage…(IntenSify) | Phase 1 | terminated | Aug 10, 2022 | German Cancer Research Center | lack of efficacy paired with high toxicity | Safety / toxicity |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of… | N/A | withdrawn | Aug 17, 2018 | Fifth Affiliated Hospital, Sun Yat-Sen University | No participents enrolled | Enrollment / accrual |
| NCT03889093 | Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The… | N/A | terminated | Mar 26, 2019 | University of Minnesota | PI Left Institution | Investigator |
| NCT04866836 | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of… | Phase 2 | terminated | Apr 30, 2021 | The First Affiliated Hospital with Nanjing Medical University | The study was prematurely terminated due to difficulties in recruitment. | Enrollment / accrual |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jul 26, 2021 | Tarus Therapeutics, Inc. | Tarus is conducting clinical development under a single IND, specifically IND for TT-10 (PORT-6).… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 8, 2025source: clinicaltrials